Toxys hosts a session at the 11th World Congress on Alternatives and Animal Use in the Life Sciences
Toxys will be hosting a session with guest speakers from Unilever and Health Canada at the The 11th World Congress on Alternatives and Animal Use in the Life Science (WC11).
Every year, large numbers of new compounds are being developed for a wide range of purposes. Due to the large numbers of compounds that require safety assessment, there is an increasing demand for rapid and reliable in vitro assays that assess their toxicity in an early phase of drug or product development. At the same time, there is a strong demand to reduce animal testing. We have therefore developed various in vitro cell-based assays for chemical safety assessment with the focus on understanding the mode-of-action (MoA) of toxic compounds.
ToxTracker is a unique stem cell-based reporter assay for reliable genotoxicity and carcinogenicity hazard identification. The ToxTracker assay reliably identifies genotoxic compounds and provides insight into their mode-of-action. The assay is able to discriminate between direct DNA reactivity and indirect genotoxicity related to oxidative stress or protein damage and can differentiate between genotoxic compounds with a clastogenic or aneugenic MoA. Various extensions of ToxTracker to further investigate the MoA of genotoxic compounds are combined in the ToxTracker suite.
ReproTracker is a human induced pluripotent stem cell (hiPSC)-based biomarker assay that follows the differentiation during early embryonic development. The hiPSCs are differentiate into the primordial endoderm, ectoderm and mesoderm germ layers and further matured into hepatocytes, cardiomyocytes, and neural rosettes. The differentiation process is followed by morphological profiling and expression pattern analysis of cell-specific biomarkers. In this system, decrease in the expression of the biomarker genes and morphology disruption of the differentiated cells following compound treatment indicated teratogenicity.
In this session we will address the latest developments and applications of these novel tools for the fields of genotoxicity and developmental toxicity. We will discuss how results from the in vitro assays can be extrapolated to in vivo exposures and how these assays help in replacing or reducing animal testing by providing reliable in vitro data.
Program and speakers:
G. Hendriks CEO, Toxys
Human stem-cell based assay for in vitro assessment of developmental toxicity
A. Jamalpoor, Senior Scientist, Toxys
Integration of ReproTracker into a next generation risk assessment (NGRA) approach
I. Muller, Unilever
ToxTracker, a highly quantitative new approach method for mechanistic genotoxicity assessment
I. Brandsma, Senior Scientist, Toxys
Application of in vitro to in vivo extrapolation to ToxTracker Data for Point of Departure Derivation.
M. Beal, Health Canada
General discussion and conclusions